Compare RUN & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | AAPG |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 2.9B |
| IPO Year | 2015 | 2025 |
| Metric | RUN | AAPG |
|---|---|---|
| Price | $17.58 | $32.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | $20.63 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 9.3M | 5.1K |
| Earning Date | 11-06-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,316,656,000.00 | $54,524,554.00 |
| Revenue This Year | $18.66 | N/A |
| Revenue Next Year | $6.33 | $368.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.79 | N/A |
| 52 Week Low | $5.38 | $16.50 |
| 52 Week High | $22.44 | $48.45 |
| Indicator | RUN | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 50.39 |
| Support Level | $17.35 | $30.00 |
| Resistance Level | $20.31 | $33.09 |
| Average True Range (ATR) | 1.31 | 0.83 |
| MACD | -0.11 | 0.14 |
| Stochastic Oscillator | 16.70 | 72.07 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.